NCT04480710View on ClinicalTrials.gov

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

June 29, 2021

Study Completion Date

October 30, 2021

Conditions
NASH - Nonalcoholic SteatohepatitisFibrosis, LiverNAFLD - Nonalcoholic Fatty Liver Disease
Interventions
DRUG

CRV431 75mg

1 x 75mg softgel capsule

DRUG

Placebo (1 softgel)

1 x placebo softgel capsule

DRUG

CRV431 225mg

3 x 75mg softgel capsule

DRUG

Placebo (3 softgels)

3 x placebo softgel capsule

Trial Locations (10)

30060

Gastrointestinal Specialists of Georgia, Marietta

32127

Progressive Medical Research, Port Orange

33155

La Salud Research, Inc., Miami

34249

Covenant Research, LLC., Sarasota

43213

Aventiv Research Inc., Columbus

78209

Quality Research Inc., San Antonio

78229

Pinnacle Research Group, San Antonio

92064

Alliance Clinical Research, Poway

92866

Conquest Clinical Research, Orange

00927

FDI Clinical Research, San Juan

Sponsors
All Listed Sponsors
lead

Hepion Pharmaceuticals, Inc.

INDUSTRY